Lung ultrasound findings following COVID-19 hospitalization: A prospective longitudinal cohort study - 11/05/22
, Elke Platz b, Alia Saed Alhakak a, Morten Sengeløv a, Jakob Øystein Simonsen a, Niklas Dyrby Johansen a, Filip Søskov Davidovski a, Jacob Christensen a, Henning Bundgaard c, Christian Hassager c, Reza Jabbari c, Jørn Carlsen c, Ole Kirk d, Matias Greve Lindholm e, Ole Peter Kristiansen f, Olav Wendelboe Nielsen f, Klaus Nielsen Jeschke g, Charlotte Suppli Ulrik h, Pradeesh Sivapalan i, Kasper Iversen a, Jens Ulrik Stæhr Jensen i, j, Morten Schou a, Søren Helbo Skaarup k, Mats Christian Højbjerg Lassen a, Kristoffer Grundtvig Skaarup a, Tor Biering-Sørensen a, l
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
Lung ultrasound (LUS) is a useful tool for diagnosis and monitoring in patients with active COVID-19-infection. However, less is known about the changes in LUS findings after a hospitalization for COVID-19.
Methods |
In a prospective, longitudinal study in patients with COVID-19 enrolled from non-ICU hospital units, adult patients underwent 8-zone LUS and blood sampling both during the hospitalization and 2–3 months after discharge. LUS images were analyzed blinded to clinical variables and outcomes.
Results |
A total of 71 patients with interpretable LUS at baseline and follow up (mean age 64 years, 61% male, 24% with acute respiratory distress syndrome (ARDS)) were included. The follow-up LUS was performed a median of 72 days after the initial LUS performed during hospitalization. At baseline, 87% had pathologic LUS findings in ≥1 zone (e.g. ≥3 B-lines, confluent B-lines or subpleural or lobar consolidation), whereas 30% had pathologic findings at follow-up (p < 0.001). The total number of B-lines and LUS score decreased significantly from hospitalization to follow-up (median 17 vs. 4, p < 0.001 and 4 vs. 0, p < 0.001, respectively). On the follow-up LUS, 28% of all patients had ≥3 B-lines in ≥1 zone, whereas in those with ARDS during the baseline hospitalization (n = 17), 47% had ≥3 B-lines in ≥1 zone.
Conclusion |
LUS findings improved significantly from hospitalization to follow-up 2–3 months after discharge in COVID-19 survivors. However, persistent B-lines were frequent at follow-up, especially among those who initially had ARDS. LUS seems to be a promising method to monitor COVID-19 lung changes over time.
Clinicaltrials.gov ID |
NCT04377035.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Among 71 COVID-19 survivors, pathologic findings on LUS improved significantly from hospitalization to 2–3 months after discharge. |
• | Persistent B-lines were frequent at follow-up, especially among those who developed ARDS during the hospitalization. |
• | LUS seems to be a promising method to monitor COVID-19 lung changes over time. |
Keywords : Lung ultrasound, COVID-19, Longitudinal follow-up
Abbreviations : LUS, CT, AHF, ARDS, IQR
Plan
Vol 197
Article 106826- juin 2022 Retour au numéro
Article précédent
- Chronic obstructive pulmonary disease is associated with a higher risk of functional gastrointestinal disorders
- Yu-Chi Chiu, Wei-Pin Chang, Gau-Jun Tang, Tzuo-Yun Lan, Kang-Yun Lee, Vincent Yi-Fong Su
- Potential clinical implications of targeted spirometry for detection of COPD: A contemporary population-based cohort study
- Yunus Çolak, Børge G. Nordestgaard, Jørgen Vestbo, Shoaib Afzal, Peter Lange
Bienvenue sur EM-consulte, la référence des professionnels de santé.